Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

COPD: Update Bulletin [July 2016]

Product Code:
596200591
Publication Date:
July 2016
Format:
PDF
Price:
£1,140

This edition presents key opinion leader (KOL) views on recent developments in the chronic obstructive pulmonary disease (COPD) market. Topics covered include the clinical relevance of the latest clinical trial data presented by GlaxoSmithKline (GSK) at the 2016 American Thoracic Society International Conference in San Francisco, California (ATS 2016) in respect of two of the company’s dual-combination products for the treatment of COPD: the ICS/LABA Breo Ellipta (fluticasone furoate/vilanterol) and the LABA/LAMA Anoro Ellipta (vilanterol/umeclidinium). KOLs’ views on the perceived clinical benefits of several closed triple-combination therapies, currently in late-stage development, are also explored. 

Business Questions:

  • GSK reports positive outcomes with the ICS/LABA Breo Ellipta (fluticasone furoate/vilanterol) from the SUMMiT trial, but how well has this data been received amongst prescribers?
  • What is the future of GSK’s Breo Ellipta in light of the latest clinical trial data?
  • What is the clinical relevance of GSK’s head-to-head trial comparing the safety and efficacy of the ICS/LABA Anoro Ellipta (vilanterol/umeclidinium) against established LAMA, Spiriva (tiotropium)?
  • Will the latest clinical trial data from GSK encourage increased prescribing of Anoro Ellipta?
  • What is the clinical demand for closed triple-combination products and what advantages do they offer over existing therapies?
  • Do any of the triple combination therapies currently in late-stage development have the potential to become practice changing in the treatment of COPD?



customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved